NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS   RESOURCES  
Small Claims Guide   Class Actions   Lemon Laws   FAQ   Newsletters  


Complain about a product or service

Automotive    Education    Employment    Electronics    Family    Finance    Health    Homeowners    Pets    Shopping    Travel   



NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Public Citizen Seeks Avandia Ban

Consumer group says diabetes drug is too dangerous for use





October 30, 2008

Diabetes

FDA Warns of Bogus Insulin
Public Citizen Seeks Avandia Ban
Blood Sugar Monitor Can Detect Early Diabetes
Studies Find Link Between Diabetes and Alzheimer's
Avandia Maker Failed To Report Required Data
Prediabetes: What You Should Know
Study: Large-Breasted Women More Diabetes-Prone
U.S. Diet Dishes Up Diabetes
Weight-Loss Surgery Seen Beneficial to Diabetics
Lack of Deep Sleep May Increase Diabetes Risk
Study: Avandia May Do More Harm than Good
FDA Orders New Warning For Avandia
U.S. Kidney Disease on the Rise
Fish Oil May Fight Diabetes
Avandia vs. Actos: A Doctor's Advice
Avandia Linked to 42% Greater Risk of Heart Attack
Soft Drink Sweetener Linked to Diabetes in Kids
Diabetes Drugs to Get 'Black Box' Warnings
FDA Rejects Advice to Pull Avandia From Market
FDA Advised to Pull Avandia From Market
Avandia, Other Diabetes Drugs Increase Risk of Heart Failure
Dairy Products May Protect Against Metabolic Syndrome
Portion-Control Dishes May Help Obese Diabetics
FDA Issues Safety Alert on Diabetes Drug Avandia
Stem Cell Treatment May "Cure" Diabetes
Diabetes Risk May Be In The Genes
Holiday Gluttony Can Spell Disaster for Undiagnosed Diabetics
Malaria Drug May Fight Common Cause of Diabetes, Heart Disease
Feds Attack Fake Diabetes Cures
FDA Approves New Treatment for Diabetes
Feds Warn Of Counterfeit Diabetes Tests
Study: Weightlifting Helps Overweight Teens Avoid Diabetes
Researchers Say They Can Reverse Type 1 Diabetes
Study: Obesity Major Factor in Diabetes Epidemic
Too Much, Too Little Sleep Linked To Diabetes In Men
Procedure Cures Some Diabetic Mice
Ethnicity Skews Diabetes' Effect on Heart
Pig Cells May Be Useful in Diabetes Treatment
Protein Triggers Fat-Saturated Cell Death
FDA Approves Diabetes Inhaler Exubera
FDA Panel Greenlights Diabetes Inhaler
Breastfeeding May Decrease Diabetes Risk
Low-Fat Dairy Products May Lower Diabetes Risk in Men
Scientists Find Diabetes "Switch"
New Diabetes Treatment Approved
Knowledge of Diabetes Doesn't Always Affect Outcomes
Moderate Exercise Helpful to Diabetes-Prone Women
Life Expectancy Increases; Diabetes Epidemic Worsens

The consumer group Public Citizen has petitioned the Food and Drug Administration (FDA) to institute an immediate ban of the diabetes drug Avandia. The group says the drug is dangerous and can cause death from liver failure and many other life-threatening risks.

New research released by Public Citizen about the drug, used to treat Type 2 diabetes, comes as a working group with representatives from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes, unanimously advised against using Avandia, whose generic name is rosiglitazone, because of their concerns about the drug's risks.

This statement appears in the newly published issue of Diabetes Care, the ADA's peer-reviewed medical journal. Despite a significant decrease in its use since publication of a study linking it to increased risk of heart attacks, approximately 10,000 prescriptions a day are still filled for Avandia, which is sold by Glaxo-SmithKline.

The FDA issued a safety alert for Avandia in May 2007.

Public Citizen said it has identified 14 cases of Avandia-induced liver failure, including 12 deaths. The group said the cases were derived from the FDA Adverse Event Reporting System after careful review of the agency's MedWatch forms, which are submitted to the agency when adverse drug reactions are suspected.

Liver toxicity is only the most recently noted danger linked to Avandia; Public Citizen has encouraged diabetes sufferers to avoid taking the drug because it increases the risk of heart attack approximately 40 percent, doubles the risk of heart failure and bone fractures, and increases the risk of anemia and vision loss from macular edema, a swelling of the retina caused by fluids accumulating in the eye.

There were 39 times more reports of macular edema per million prescriptions filled for Avandia than for an older diabetes drug, glipizide.

Avandia prescriptions fell sharply following a May 2007 study published in The New England Journal of Medicine connecting the drug with increased heart attack risk. In 2006, the number of people taking the drug peaked at 13.2 million. Since then, that number has dropped to 4.6 million for the last full year. This means that about 10,000 prescriptions a day are still being filled for this dangerous drug.

"The scientific consensus against Avandia is overwhelming," said Dr. Sidney Wolfe, director of Public Citizen's Health Research Group. "The timing of these findings should give the FDA the momentum it needs to act swiftly to prevent further needless deaths and health damage by banning this drug."

The group says safer, more effective drugs for Type 2 diabetes include metformin (brand name Glucophage) and glipizide (brand name Glucotrol). Pioglitazone (sold as Actos), a drug in the same family as Avandia, is not recommended, as it shares most of Avandia's toxicities – except for the risk of heart attack – and the ADA does not number it among the preferred therapies for most diabetics.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.



Asterpix

CONSUMER NEWS

SAFETY RECALLS

PRINT, ETC.

Print This

Email This


FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!

MOST-VIEWED PAGES

NEW COMPLAINTS

Hey there! ConsumerAffairs.com is using Twitter.
Twitter is a free service that lets you keep in touch throughout the day. Join today to start receiving ConsumerAffairs.com's updates.



Back to the top |

Advertisement


Custom Search
AUTOMOTIVE
• Dealers
• Manufacturers
• Service
• Extended Warranties
• Lemon Laws
• Recalls
• Tires
• Transporters

FAMILY
• Aging
• Children, Parenting
• Recalls
• Dating
• Education
• Entertainment
• Pets
• Weddings
FINANCE
• Annuities
• Banks
• Credit Cards
• Debt Collection
• Debt Counseling
• Insurance
• Investing
• Loans
• Mortgages
• Payday Loans
• Student Loans
• Tax Prep

HEALTH
• Doctors
• Drugs, Pharmacies
• Health Clubs
• Hearing Care
• Hospitals
• Nursing Homes
• Nutrition, Diets
• Vision Care
• Weight Loss
HOMEOWNERS & RENTERS
• Appliances
• Cookware
• Furniture
• Home Improvements
• Lawn & Garden
• Movers
• Pools & Spas
• Realtors, Rental Agents
• Recalls
• Utilities

ELECTRONICS
• Cable TV/DBS
• Cameras
• Cell Phones
• Computers
• Home Electronics
• Internet Access
• Local Phone Service
• Long Distance
• VoIP
SHOPPING
• In-Home
• Online
• Retail Stores
• Sporting Goods
• Supermarkets
• Telemarketers

TRAVEL
• Airlines
• Bus Lines
• Car Rental
• Cruises
• Hotels
• Travel Agents
• Trains

RESOURCES
• Class Actions
• Complaint Form
• Small Claims Guide
• Lemon Laws
CONSUMER NEWS
• Latest News
• Automotive
• Telecom
• Financial
• Health
• Homeowners
• Scams
• Seniors
• Travel
• More ...

RECALLS
• Automotive
• Children's Products
• Drugs
• Food
• Household Products
• Sporting Goods

ABOUT US
• FAQ
• Privacy Policy
• Advertise With Us
• Newsroom
• Syndication
• Terms of Use

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.